| Oct 31 |
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
|
| Sep 23 |
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
|
| Sep 13 |
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
|
| Sep 9 |
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
|
| Sep 4 |
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
|
| Aug 9 |
SAB Biotherapeutics GAAP EPS of -$0.79
|
| Aug 8 |
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
|
| Aug 5 |
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
|
| Jul 31 |
SAB Biotherapeutics names Lucy To as CFO
|
| Jul 31 |
SAB BIO Appoints Lucy To as Chief Financial Officer
|
